Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death

Atherosclerosis

Volumn 152, Issue 1, 2000, Pages 217-227

  Knapp, Anita C ^a   Huang, Jinwen ^a   Starling, Gary ^a   Kiener, Peter A ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Cell death; Cytokines; FasL; Hydroxymethylglutaryl CoA (HMG CoA) reductase inhibitors; Smooth muscle cells

Indexed keywords

ATORVASTATIN; CYTOKINE; FARNESYL TRANS TRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

APOPTOSIS; ARTICLE; ATHEROMA; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CELL DEATH; CHOLESTEROL BLOOD LEVEL; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIGAND BINDING; MORBIDITY; MORTALITY; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER;

APOPTOSIS; CELL SURVIVAL; CELLS, CULTURED; COMPARATIVE STUDY; CORONARY VESSELS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; HEPTANOIC ACIDS; HUMAN; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MEMBRANE GLYCOPROTEINS; MUSCLE, SMOOTH, VASCULAR; PRAVASTATIN; PYRROLES; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; SIMVASTATIN; SUPPORT, NON-U.S. GOV'T;

EID: 0034283536     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00462-1     Document Type: Article

References (56)

1. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl. J. Med. 335:1996;1001-1009.
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease (4S). Lancet. 344:1994;1383-1389.
3. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. New Engl. J. Med. 333:1995;1301-1307.
4. Ross R. The pathogenesis of atherosclerosis: perspective for the 1990s. Nature. 1993:362;801-809.
5. Libby P., Geng Y.-J., Sukhova G.K., Simon D.I., Lee R.T. Molecular determinants of atherosclerotic plaque vulnerability. Ann. N.Y. Acad. Sci. 811:1997;134-145.
6. Bellosta S., Bernini F., Ferri N., Quarato P., Canavesi M., Arnaboldi L. et al. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis. 137:1998;S101-S109.
7. Massy Z.A., Keane W.F., Kasiske B.L. Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? Lancet. 347:1996;102-103.
8. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study [WOSCOPS]. Circulation. 97:1998;1440-1445.
9. Kiener P.A., Davis P.M., Murray L., Youssef S., Rankin B.M., Kowala M. Characterization of the differences in the pro-inflammatory effects of HMG CoA reductase inhibitors. European Atherosclerosis Society 70th EAS Congress, Geneva, Switzerland, September 6-9, 1998. 1998;. (abstract).
10. Negre-Aminou P., van Vliet A.K., van Erck M., van Thiel G.C.F., van Leeuwen R.E.W., Cohen L.H. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors: comparison with other human cell types. Biochem. Biophys. Acta. 1345:1997;259-268.
11. Colli S., Eligini S., Lalli M., Camera M., Paoletti R., Tremoli E. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscler. Thromb. Vasc. Biol. 17:1997;265-272.
12. Pirillo A., Jacoviello C., Longoni C., Radaelli A., Catapano A.L. Simvastatin modulates the heat shock response and cytotoxicity mediated by oxidized LDL in cultured human endothelial smooth muscle cells. Biochem. Biophys. Res. Commun. 231:1997;437-441.
13. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature. 343:1990;425-430.
14. Libby P., Ross R. Cytokines and growth regulatory molecules in atherosclerosis. Fuster V., Ross R., Topol E.J. Atherosclerosis and coronary artery disease. 1996;585-594 Lippincott-Raven, Philadelphia, PA.
15. Libby P. Atheroma: more than mush. Lancet. 348:1996;S4-S7.
16. DeGraba T.J. Expression of inflammatory mediators and adhesion molecules in human atherosclerotic plaque. Neurology. 49:1997;S15-S19.
17. Buja L.M., Willerson J.T. Role of inflammation in coronary plaque disruption. Circulation. 89:1994;503-505.
18. Van der Wal A.C., Becker A.E., van der Loos C.M., Das P.K. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 89:1994;36-44.
19. Kockx M.M., Herman A.G. Apoptosis in atherogenesis: implications for plaque destabilization. Eur. Heart J. 19:1998;G23-G28.
20. Geng Y.-J., Henderson L.E., Levesque E.B., Muszynski M., Libby P. Fas is expressed in human atherosclerotic intima and promotes apoptosis of cytokine-primed human vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 17:1997;2200-2208.
21. Cai W.-j, Devaux B., Schaper W., Schaper J. The role of Fas/APO 1 and apoptosis in the development of human atherosclerotic lesions. Atherosclerosis. 131:1997;177-186.
22. Crisby M., Kallin B., Thyberg J., Zhivotovsky B., Orrenius S., Kostulas V. et al. Cell death in human atherosclerotic plaques involves both oncosis and apoptosis. Atherosclerosis. 130:1997;17-27.
23. Bennett M.R., Boyle J.J. Apoptosis of vascular smooth muscle cells in atherosclerosis. Atherosclerosis. 138:1998;3-9.
24. Schwartz S.M., deBlois D., O'Brien E.R.M. The intima. Soil for atherosclerosis and restenosis. Circ. Res. 77:1995;445-465.
25. Geng Y.-J., Libby P. Evidence for apoptosis in advanced human atheroma. Colocalization with interleukin-1β-converting enzyme. Am. J. Pathol. 147:1995;251-266.
26. Kockx M.M., DeMeyer G.R.Y., Muhring J., Jacob W., Bult H., Herman A.G. Apoptosis and related proteins in different stages of human atherosclerotic plaques. Circulation. 97:1998;2307-2315.
27. Bennett M., Macdonald K., Chan S.-W., Boyle J.J., Weissberg P.L. Cooperative interactions between RB and p53 regulate cell proliferation, cell senescence, and apoptosis in human vascular smooth muscle cells from atherosclerotic plaques. Circ. Res. 82:1998;704-712.
28. Perlman H., Maillard L., Krasinski K., Walsh K. Evidence for the rapid onset of apoptosis in medial smooth muscle cells after balloon injury. Circulation. 95:1997;981-987.
29. Geng Y.-J. Regulation of programmed cell death or apoptosis in atherosclerosis. Heart Vessels. 12:1997;76-80.
30. Laufs U., La Fata V., Plutzky J., Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 97:1998;1129-1135.
31. Kiener P.A., Davis P.M., Starling G.C., Mehlin C., Klebanoff S.J., Ledbetter J.A. et al. Differential induction of apoptosis by Fas-Fas ligand interactions in human monocytes and macrophages. J. Exp. Med. 185:1996;1511-1516.
32. Geng Y.-J., Wu Q., Muszynski M., Hansson G.K., Libby P. Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-γ, tumor necrosis factor-α and interleukin-1β Arterioscler. Thromb. Vasc. Biol. 16:1996;19-27.
33. Guijarro C., Blanco-Colio L.M., Ortego M., Alonso C., Ortiz A., Plaza J.J. et al. 3-Hydroxy-3-methylglutaryl Coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ. Res. 83:1998;490-500.
34. Corsini A., Pazzucconi F., Arnaboldi F., Pfister L., Fumagalli R., Paoletti R. et al. Direct effects of statins on the vascular wall. J. Cardiovasc. Pharmacol. 31:1998;773-778.
35. Baetta R., Donetti E., Comparato C., Calore M., Rossi A., Teruzzi C. et al. Proapoptotic effect of atorvastatin on stimulated rabbit smooth muscle cells. Pharmacol. Res. 36:1997;115-121.
36. Jovinge S., Crisby M., Thyberg J., Nilsson J. DNA fragmentation and ultrastructural changes of degenerating cells in atherosclerotic lesions and smooth muscle cells exposed to oxidized LDL in vitro. Arterioscler. Thromb. Vasc. Biol. 17:1997;2225-2231.
37. Rosenson R.S., Tangney C.C. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. J. Am. Med. Assoc. 279:1998;1643-1650.
38. Serajuddin A.T.M., Ranadive S.A., Mahoney E.M. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. J. Pharm. Sci. 80:1991;830-834.
39. Hamelin B.A., Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol. Sci. 19:1998;26-37.
40. Goldman F., Hohl R.J., Crabtree J., Lewis-Tibesar K., Koretzky G. Lovastatin inhibits T cell antigen receptor signaling independent of its effects on ras. Blood. 88:1996;4611-4619.
41. Neuvonen P.J., Kantola T., Kivistoe K.T. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin. Pharmacol. Ther. 63:1998;332-341.
42. Lilja J.J., Kivisto K.T., Neuvonen P.J. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin. Pharmacol. Ther. 64:1998;477-483.
43. Duggan D.E., Chen I.-W., Bayne W.F., Halpin R.A., Duncan C.A., Schwartz M.S. et al. The physiological disposition of lovastatin. Drug Metab. Dispos. 17:1989;166-173.
44. Sata M., Walsh K. TNFα regulation of Fas ligand expression on vascular endothelium modulates leukocyte extravasation. Nat. Med. 4:1998;415-420.
45. Richardson B.C., Lalwani N.D., Johnson K.J., Marks R.M. Fas ligation triggers apoptosis in macrophages but not endothelial cells. Eur. J. Immunol. 24:1994;2640-2645.
46. Longthorne V.L., Williams G.T. Caspase activity is required for commitment to Fas-mediated apoptosis. EMBO J. 13:1997;3805-3812.
47. Tamanoi F. Inhibition of Ras farnesyltransferases. Trends Biochem. Sci. 18:1993;349-353.
48. Stark J.R. W.W., Blaskovich M.A., Johnson B.A., Qian Y., Vasudevan A., Pitt B. et al. Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells. Am. J. Physiol. 275:1998;L55-L63.
49. Ivessa N.E., Gravotta D., De Lemos-Chiarandini C., Kreibich G. Functional protein prenylation is required for the brefeldin A-dependent retrograde transport from the Golgi apparatus to the endoplasmic reticulum. J. Biol. Chem. 272:1997;20828-20834.
50. Bennett M., Macdonald K., Chan S.-W., Luzio J.P., Simari R., Weissberg P. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science. 282:1998;290-293.
51. Igarashi M., Takeda Y., Mori S., Ishibashi N., Komatsu E., Takahashi K. et al. Suppression of neointimal thickening by a newly developed HMG-CoA reductase inhibitor, BAYw6228 and its inhibitory effect on vascular smooth muscle cell growth. Br. J. Pharmacol. 120:1997;1172-1178.
52. Bandoh T., Mitani H., Niihashi M., Kusumi Y., Ishikawa J., Kimura M. et al. Inhibitory effect of fluvastatin at doses insufficient to lower serum lipids on the catheter-induced thickening of intima in rabbit femoral artery. Eur. J. Pharmacol. 315:1996;37-42.
53. Soma M., Donetti E., Parolini C., Mazzini G., Ferrari C., Fumagalli R. et al. HMG-CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits. Arterioscler. Thromb. 13:1993;571-578.
54. Gellman J., Ezekowitz M.D., Sarembock I.J., Azrin M.A., Nochomowitz L.E., Lerner E. et al. Effect of lovastatin on intimal hyperplasia after balloon angioplasty: a study in an atherosclerotic hypercholesterolemic rabbit. J. Am. Coll. Cardiol. 17:1991;251-259.
55. Mitchinson M.J., Hardwick S.J., Bennett M.R. Cell death in atherosclerotic plaques. Curr. Opin. Lipidol. 7:1996;324-329.
56. Bennett M.R., Evan G.I., Schwartz S.M. Apoptosis of human smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J. Clin. Invest. 95:1995;2266-2274.